title: [Comparative study of first-line ceftriaxone and amikacin in the treatment of severe urinary tract infections in the adult].
abstract: After randomization in 2 groups of 20, 40 adult patients with a severe urinary tract infection (post-urologic surgery, pyelonephritis, prostatitis, neurologic bladder dysfunction, Foley catheter) received as first-line therapy, ceftriaxone (CFX) 1 g/24 h im or amikacin (AMK) 500 mg/24 h im during at least 5 days. The clinical and bacteriological efficiency and the tolerance of the 2 agents are equivalent. In the 2 groups, all patients but one are clinically cured. In the CFX group, 2 patients had resistant organisms (E. cloacae, strepto D) to first-line antibiotic. 48 hours after the beginning and at the end of the treatment, the percentage of urine sterilization was respectively 65 and 88 in the CFX group and 50 in the AMK group. In both groups, 60% of the patients showed negative first-month follow-up urine specimen. Underlying urinary tract pathology contributed to persistence of the original infecting organism, reinfection or relapse; the responsible isolate remained sensitive to the first-line antibiotic.
authors.forename: J Y
authors.initials: JY
authors.lastname: Lepage
authors.forename: C
authors.initials: C
authors.lastname: Juge
authors.forename: A
authors.initials: A
authors.lastname: Cozian
authors.forename: E
authors.initials: E
authors.lastname: Espaze
authors.forename: A E
authors.initials: AE
authors.lastname: Reynaud
authors.forename: R
authors.initials: R
authors.lastname: Souron
authors.forename: D
authors.initials: D
authors.lastname: Baron
mesh_terms: D000328:Adult; D000368:Aged; D000583:Amikacin / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000627:therapeutic use*; D004341:Drug Evaluation; D004361:Drug Tolerance; D006801:Humans; D008875:Middle Aged; D011897:Random Allocation; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D002443:Ceftriaxone; D000583:Amikacin
vernacular_title: Etude comparative de la ceftriaxone et de l'amikacine en première intention dans le traitement des infections urinaires sévères de l'adulte.